HNPOLY(SZ:300630) Xin Lang Cai Jing·2026-01-09 02:50Core Viewpoint - The article discusses the legal actions taken against Puli Pharmaceutical due to false reporting of sales revenue and profits, leading to investor claims and a recent appeal by the company against a favorable ruling for investors [1][3]. Financial Misreporting - Puli Pharmaceutical falsely reported sales revenue and profits by fabricating sales of finished and raw pharmaceutical products from 2021 to 2022. In 2021, the company overstated revenue by 436,606,838.34 yuan, which was 28.94% of the reported revenue, and overstated profit by 308,018,435.49 yuan, accounting for 65.88% of the reported profit [1][5]. - In 2022, the company overstated revenue by 456,639,341.72 yuan, representing 25.28% of the reported revenue, and overstated profit by 387,417,257.52 yuan, which was 88.27% of the reported profit [1][4]. Additional Revenue Misstatements - Puli Pharmaceutical also misreported revenue from non-controlling trade activities, leading to an additional overstatement of revenue by 77,997,346.38 yuan in 2021 (5.17% of reported revenue) and 59,259,735.84 yuan in 2022 (3.28% of reported revenue) [2][4]. Legal Proceedings and Investor Claims - The law firm representing investors, Shanghai Jiucheng Law Firm, is continuing to accept claims from investors who purchased Puli Pharmaceutical stock between April 26, 2022, and April 17, 2024, and subsequently sold or held the stock after April 17, 2024 [3][5]. - The firm has a history of successfully representing investors in similar cases, with nearly 200 cases won or settled favorably [3].